Main Entry Criteria. Patients aged 16 to 65 years with medication-resistant partial seizures with or without secondary generalization when on one to two antiepileptic drugs (AEDs)

Comparator. Add-on levetiracetam 1,000 or 2,000 mg/day versus placebo

Number of Patients. 324

Primary Outcome Variable; Important Secondary Variables. Mean weekly seizure frequency, absolute and percentage seizure reduction, number of seizure-free patients, and 50% and 75% responder rates

Results. Both levetiracetam dosages significantly reduced mean partial seizure frequency compared to placebo. Significantly more patients receiving either levetiracetam dose were 50% or 75% responders compared to placebo. A significantly greater 50% responder rate was seen with the 2,000 mg/day dosage of levetiracetam compared to the 1,000 mg/day dosage of levetiracetam.

Main Entry Criteria. Patients aged 16 to 70 years with medication-resistant partial seizures with or without secondary generalization on one AED

Comparator. Add-on levetiracetam 3,000 mg/day (divided b.i.d.) versus placebo followed by monotherapy in 50% responders

Number of Patients. 286 patients entered the add-on phase; 86 were eligible for the monotherapy phase.

Primary Outcome Variable; Important Secondary Variables. Percentage of patients who completed the monotherapy phase, seizure frequency, 50% responder rate

Results. Significantly more patients receiving levetiracetam completed the study (including monotherapy phase) compared to placebo. In the add-on phase, median partial seizure frequency and median percentage seizure reduction were decreased significantly compared to placebo. The 50% responder rate was significantly greater with levetiracetam than with placebo in the add-on phase.

Main Entry Criteria. Patients aged 16 to 65 years with medication-resistant partial seizures with or without secondary generalization on one to two AEDs

Comparator. Add-on levetiracetam 1,000 or 2,000 mg/day (both divided b.i.d.) versus placebo

Number of Patients. 324

Primary Outcome Variable; Important Secondary Variables. Mean partial seizure frequency, seizure frequency by seizure subtypes, 50% responder rate, number of seizure-free patients

Results. Levetiracetam significantly reduced partial seizure frequency compared to placebo. No significant differences were identified between the two dosages. No significant differences were found in seizure reduction according to seizure subtype. The 50% responder rate was significantly greater in both levetiracetam groups compared to placebo. No significant differences were found in responder rates between the two dosages.

Main Entry Criteria. Patients aged 16 to 70 years with medication-resistant partial
seizures with or without secondary generalization on one to two AEDs

Comparator. Add-on levetiracetam 1,000 or 3,000 mg/day versus placebo

Number of Patients. 294

Primary Outcome Variable; Important Secondary Variables. Mean weekly partial seizure frequency, median percentage reduction in seizures, 50% responder rate, and number of seizure-free patients

Results. Partial seizure frequency was significantly lower for both levetiracetam groups compared to placebo, and 50% responder rate was significantly higher in both levetiracetam groups compared to placebo. A significantly greater number of patients in the 3,000 mg/day levetiracetam group were seizure free compared to placebo.

Main Entry Criteria. Patients aged 16 to 70 years with medication-resistant epilepsy (mixed group—partial with or without secondary generalization, primary generalized tonic-clonic [GTC]) on one to three AEDs

Comparator. Add-on levetiracetam 2,000 or 4,000 mg/day versus placebo

Number of Patients. 119

Primary Outcome Variable; Important Secondary Variables. 50% responder rate, seizure frequency by seizure type, number of seizure-free patients